Department of Dermatology, Amiens University hospital, Amiens.
Dermatol Online J. 2020 Oct 15;26(10):13030/qt4w21m02k.
Vedolizumab is a humanized monoclonal antibody that binds to the human a4β7 integrin and is approved for use in inflammatory bowel diseases. We describe a patient with severe, refractory erosive gingivostomatitis, which appeared a few days after the first dose of vedolizumab and resolved after discontinuation of the drug. We believe the gingivostomatitis to be a direct side effect of vedolizumab, rather than an extraintestinal manifestation of the underlying inflammatory bowel diseases. The clinicians need to be aware of this adverse event, which could be mistakenly considered as an extraintestinal manifestation of inflammatory bowel diseases.
维得利珠单抗是一种人源化单克隆抗体，可与人类 a4β7 整合素结合，已被批准用于炎症性肠病。我们描述了一例严重、难治性侵蚀性牙龈舌炎患者，该患者在首次接受维得利珠单抗治疗几天后出现，并在停药后消退。我们认为，牙龈舌炎是维得利珠单抗的直接副作用，而不是潜在炎症性肠病的肠外表现。临床医生需要注意这种不良事件，否则可能会误认为是炎症性肠病的肠外表现。
